EnglishPURPOSE: Our aim was to evaluate whether dronedarone authorization impacts antiarrhythmic drug prescribing in Sweden and Emilia Romagna (Italy). METHODS: Prescriptions of classes I and III antiarrhythmics, expressed as defined daily doses per thousand inhabitants per day (DDD/TID) were monthly using information collected from pharmacy-reimbursed databases. Interrupted time series analysis was applied to compare prescription data over the 2009-2011 period. RESULTS: In Emilia Romagna, the overall consumption of antiarrhythmics was six times as high as in Sweden (7.6 vs. 1.2 DDD/TID). In the first year on the market, dronedarone represented 1.0 % in Italy and 10.7 % in Sweden of the overall antiarrhythmic prescriptions. In Sweden, dronedarone authorization generated an increase in the prescription trend of antiarrhythmics (trend change +0.02; p < 0.001) without variation in amiodarone use In Emilia Romagna, dronedarone marketing did not influence the prescription pattern of either overall antiarrhythmics or amiodarone. CONCLUSIONS: Emilia Romagna and Sweden substantially differ in terms of overall antiarrhythmic use. Although clinical guidelines place dronedarone among first-choice treatments for atrial fibrillation, amiodarone prescribing was not affected in either country by the entry of dronedarone, probably due to a cautious approach by clinicians in line with regulatory recommendations and safety warnings.
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden / Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - 69:3(2013), pp. 715-720. [10.1007/s00228-012-1377-4]
| Data di pubblicazione: | 2013 | |
| Titolo: | Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. | |
| Autore/i: | Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F. | |
| Autore/i UNIMORE: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s00228-012-1377-4 | |
| Rivista: | ||
| Volume: | 69 | |
| Fascicolo: | 3 | |
| Pagina iniziale: | 715 | |
| Pagina finale: | 720 | |
| Codice identificativo ISI: | WOS:000317335200049 | |
| Codice identificativo Scopus: | 2-s2.0-84877154061 | |
| Codice identificativo Pubmed: | 22941408 | |
| Citazione: | Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden / Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - 69:3(2013), pp. 715-720. [10.1007/s00228-012-1377-4] | |
| Tipologia | Articolo su rivista |
File in questo prodotto:
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2021